Olmesartán Cinfa (Olmesartan Medoxomil)

Olmesartan medoxyl, the active ingredient in Olmesartán Cinfa, is a angiotensin II receptor blocker presented as a tablet for oral use. It is indicated for the management of hypertension in adults. GNH USA supplies Olmesartán Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartán Cinfa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxyl is used to treat high blood pressure by targeting the renin‑angiotensin system.

- Hypertension: helps lower systolic and diastolic blood pressure to reduce cardiovascular risk. - Diabetic nephropathy: slows progression of kidney damage associated with diabetes. - Heart failure: used as part of combination therapy to improve cardiac output and symptoms.

Olmesartan medoxyl may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dizziness - Headache - Fatigue - Nasal congestion - Diarrhea - Upper respiratory tract infection

Serious or Rare Side Effects: - Angio‑edema - Hyperkalemia - Acute kidney injury - Severe hypotension - Liver enzyme elevation - Allergic skin reactions

When prescribing Olmesartan medoxyl, clinicians should consider several safety aspects.

- Renal function: assess baseline kidney function and monitor periodically. - Electrolytes: check serum potassium, especially if combined with potassium‑sparing diuretics. - Pregnancy: avoid use during the second and third trimesters due to fetal toxicity. - Elderly patients: start at lower doses and monitor blood pressure response. - Drug interactions: review concomitant medications for additive hypotensive effects. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxyl can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Aliskiren: combined use in diabetic patients may increase risk of renal impairment. - Potassium‑sparing diuretics: may cause dangerous hyper‑kalemia. - NSAIDs: can blunt antihypertensive effect and affect renal function.

Moderate Interactions (Monitor Closely): - ACE inhibitors: concurrent use may increase risk of hypotension and renal dysfunction. - Lithium: may raise lithium levels, necessitating serum monitoring. - Thiazide diuretics: may enhance antihypertensive effect, requiring blood pressure checks.